成都先导药物开发股份有限公司关于股东减持股份计划公告

Core Viewpoint - The announcement details a share reduction plan by Shenzhen Jun Tian Investment Enterprise (Limited Partnership), which holds 10,067,751 shares of Chengdu Xian Dao Pharmaceutical Development Co., Ltd., representing 2.51% of the company's total share capital [2][3][4]. Group 1: Shareholder Reduction Plan - Shenzhen Jun Tian plans to reduce its holdings of 10,067,751 shares through centralized bidding and block trading, with the reduction period set from January 22, 2026, to April 21, 2026 [4]. - The shareholder has obtained the necessary approvals and is compliant with relevant regulations regarding the reduction of shares held by venture capital fund shareholders [4][6]. - The reduction will be limited to a maximum of 1% of the total shares through centralized bidding and 2% through block trading within any consecutive 30-day period [4]. Group 2: Shareholder Background - As of the announcement date, Shenzhen Jun Tian holds 10,067,751 shares, which is 2.51% of the total share capital of Chengdu Xian Dao [3]. - The shareholder has made commitments regarding the reduction, including a maximum of 50% of their shares held prior to the public offering can be reduced within two years after the lock-up period [6]. Group 3: Compliance and Regulations - The reduction plan is in accordance with the relevant laws and regulations, including the Securities Law of the People's Republic of China and specific guidelines for venture capital fund shareholders [9]. - The company will adhere to all legal and regulatory requirements during the share reduction process and will fulfill its information disclosure obligations [9].